Hemostemix is a clinical-stage biotechnology company focused on developing and commercializing a proprietary autologous cell therapy to treat ischemic diseases. ACP-01, our lead clinical stage candidate, is an autologous cell therapy for the treatment critical limb ischemia. ACP-01 is currently in a Phase 2 clinical trail in Canada, South Africa and the United States.